Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) FCF Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed FCF Margin for 5 consecutive years, with 13272.06% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin changed N/A to 13272.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 5029.7%, a N/A change, with the full-year FY2023 number at 7364.62%, down 638753.0% from a year prior.
  • FCF Margin was 13272.06% for Q4 2025 at Pliant Therapeutics, up from 2586.63% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 13272.06% in Q4 2025 to a low of 9921.77% in Q2 2023.
  • A 4-year average of 405.65% and a median of 1002.07% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: skyrocketed 58154bps in 2022, then crashed -942769bps in 2023.
  • Pliant Therapeutics' FCF Margin stood at 928.51% in 2021, then plummeted by -62bps to 1508.65% in 2022, then plummeted by -558bps to 9921.77% in 2023, then soared by 234bps to 13272.06% in 2025.
  • Per Business Quant, the three most recent readings for PLRX's FCF Margin are 13272.06% (Q4 2025), 2586.63% (Q3 2025), and 5016.44% (Q2 2025).